Introduction
Methotrexate (MTX) is the most generally administered antimetabolite in pediatric cancers which can causes considerable improvements in the long-term survival of these patients (1, 2) . Renal excretion is the major route of elimination of MTX. Almost 70%-90% of the dose is excreted unaffected in the urine, most within the first 6 hours (3). High-dose MTX (HDMTX) defined by MTX doses ≥1 g/m 2 is the important part of most chemotherapy regimens (4) . The cytotoxic effects of MTX could be amended by folinic acid (leucovorin) which allows for the administration of higher doses (up to 33.6 g/m 2 ) (5,6). MTX concentrations >1 μmol/L at 48 hours or >0.1 μmol/L at 72 hours after administration are associated with increased risk of toxicity in spite of increased leucovorin rescue (7) . Renal toxicity is a particular concern of delayed MTX elimination after administration of HDMTX (8, 9) along with other side effects including hepatotoxicity, mucositis, bone marrow suppression, secondary infection, and delays in the next course of chemotherapy (8) . MTX concentrations lower than optimal levels increase the risk of relapse (10) . Inflammation, reactive oxygen species, and neutrophil infiltration are implicated in the pathogenesis of MTX-induced renal damage (11) . The possible explanation could be development of HDMTX-induced acute renal dysfunction which is mediated by crystalinduced obstacle due to precipitation of MTX or 7-OH MTX in the nephrons, diminished renal perfusion from afferent arteriolar vasoconstriction (12) or straight toxic effect on tubular cells. It has been reported that HDMTX may lead to renal toxicity in more than 40% of patients (12) . Widemann et al reported that the incidence of MTX nephrotoxicity is 1.8% in osteosarcoma patients, but the incidence of nephrotoxicity in hematologic malignancies is not well-defined (13) . In spite of pharmacokinetic models of HDMTX to predict severe side effects, because of limitation of these models, serum MTX concentration monitoring is still a gold standard for defining patients at high risk of developing HDMTX renal toxicity (14) . However, checking plasma MTX concentrations in most oncology institutions is not always possible specially in less developed countries (15) . Hence, it is of great significance to find other means of monitoring plasma MTX concentrations. It has been hypothesized that evaluation of renal function by calculating the creatinine clearance and/or serum Cr may be appropriate means of monitoring plasma MTX concentrations instead of straight plasma measurement (3). Skärby et al previously reported that the increase in serum creatinine (Cr) concentration within the first 12 to 24 hours after the start of MTX infusion was a suitable predictor of delayed excretion of MTX in children with acute lymphoblastic leukemia (16) .
Objectives
The purpose of this study was to further assess the change of renal function after administration of HDMTX by parameters such as serum Cr and Cr clearance at various time points in children receiving HDMTX. Possible association between serum MTX concentrations and Cr clearance would be investigated to find out helpful parameters for predicting delayed MTX elimination. . The initial dose (1/5-1/6 of the full dose; no more than 500 mg) was intravenously transfused in 1 hour. The remainder was infused during the following 23 hours. In the first phase (hyper-hydration and urine alkalinization) 2-4 L/m 2 serum normal saline + 40 mEq/L 5% NaHCO3 were given at 12 hours before MTX infusion until urine pH reach >7.5 for all patients.
Patients and Methods

Patients
Leucovorin rescue
Leucovorin rescue was started 36 hours after MTX transfusion. The dose was 15 mg/m 2 for all patients despite any dose of MTX. Serum MTX concentrations were not considered to estimate the leucovorin rescue.
Sample acquisition and analysis
Measurement of plasma MTX concentrations
Blood samples were centrifuged at 3000 g for 5 minutes at room temperature in tubes without any anticoagulant. Plasma MTX concentrations were measured by high performance liquid chromatography (HPLC, Agilent 1100, USA-Mas Germany) with UV detector at 305 nm and a quantification limit of 0.01 μmol/L at 24, 48, and 96 hours after the start of treatment. A mixture of phosphate buffer and acetonitrile with pH 3.5 formed the mobile phase. Plasma levels of MTX were reported in micromoles per liter (μmol/L). Delayed elimination was defined by either MTX concentrations ≥1 μmol/L at 48 hours or ≥0.1 μmol/L at 72 hours (17) .
Measurement of Cr clearance rate and serum Cr concentration
The 24-hour urine samples were attained over the first 96 hours after beginning chemotherapy (0, 24, 48 and 96 hours) and treated with 6 N HCl as preservative. Measurement of urine Cr concentration was based on a fraction of the sample. During the last hour of urine sample attainment, a venous blood sample was drawn for serum Cr concentrations using the Cockcroft-Gault equation.
Ethical issues
The study was approved by the research ethics committee of Semnan University of Medical Sciences (#93.562629), and in all stages of research, the provisions of the Declaration of Helsinki and the directives of the ethics committee of the ministry of health were observed. All participants signed an informed consent of ethics committee.
Statistical analysis
Spearman's rank correlation was applied to determine potential effectors. Potential effectors for toxicities were then addressed by logistic regression analysis. If P value was less than 0.05 in any analysis, it was considered statistically significant. All the statistical analysis were done by SPSS 20.0 statistical software (SPSS Inc., Chicago, IL, USA).
Results
The baseline demographic and clinical characteristics of the patients were summarized in Table 1 . Most children were male (62.5 %) and had grade I disease (37.5 %) with a median age of 11.62 years (range: 5 years to 16 years). A (Table 4) . At first Spearman's rank correlation coefficient of independent variables with dependent variable determined. Our findings showed that there is an inverse correlation between Cr at 24 (r = -0.57, P = 0.020), 48 (r = -0.57, P = 0.020) and 96 (r = -0.88, P < 0.001) hours with MTX concentration (Table 3) . Correlation between Cr clearance and MTX concentration was checked with a general linear model. This model revealed that MTX changes during the time were significant (P = 0.008). Although when MTX concentration adjusted with Cr clearance, time of measurement had no significant correlation with measured Cr clearance, the interaction effect of time and Cr clearance at 48 hours is significant. In the same way Cr and MTX concentration were checked and data showed that interaction effect of time of measurement has the significant correlation with 48 hours Cr (P = 0.001) and 96 hours Cr (P = 0.018). Moreover, after Cr effect adjustment and time interaction effect, all of Cr indexes at 24 hours (P = 0.003), 48 hours (P = 0.009) and 96 hours (P = 0.044) had the significant correlation with MTX concentration in consequent measurements (Table 5) .
Discussion
It has been reported that HDMTX-regimens have nephrotoxicity incidence of about 1.8% and a mortality rate of approximately 0.1%, regardless of scheduled drug monitoring and supportive therapy (13) . Furthermore, HDMTX-induced nephrotoxicity deteriorates overall drug toxicity by delaying MTX elimination. Strict monitoring of urine output, plasma drug levels, and serum Cr levels besides urine alkalization and hydration to minimize renal toxicity are standard accessories in HDMTX regimens (7) . Other studies have reported that a serum MTX concentration of 1000 μmol/L after a 4 hours infusion and 700 μmol/L after a 6 hours infusion can attain high-quality effectiveness in the treatment of osteosarcoma. However, the administration of higher doses of MTX leads to more severe side effects. The safe range for the area under the curve has been revealed to be between 4000 mM/h and 12 000 mM/h (18) . Although, a number of population-based pharmacokinetic models of HDMTX infusion have been developed, (19) (20) (21) because of the considerable difference between patients, the clinical application of these models mainly for patients with delayed elimination of MTX is limited. Thus, we investigated the hypothesis that evaluating renal function may be an appropriate means of monitoring plasma MTX concentrations after HDMTX for pediatric cancers. Notably the Cr clearance at 48 hours after of HDMTX was significantly correlated with plasma MTX concentrations at 24, 48 and 96 hours. Likewise, 24-hour urine Cr was significantly correlated with plasma MTX concentrations at 24 hours (P = 0.003), 48 hours (P = 0.009) and 96 hours (P = 0.044). Of note, the trend of MTX concentration at 24, 48 and 96 hours was decreasing which was accurate and predictable. Several studies have found the correlation between plasma MTX concentrations and Cr clearance. Hempel et al reported a negative relationship between plasma MTX concentrations and the Cr clearance in mainly childhood patients with ALL, non-Hodgkin lymphoma, osteosarcoma, and brain tumor who received HDMTX (22) . Xu et al (23) reported a significant positive relationship between serum Cr concentrations at 24 hours and 48 hours with plasma MTX concentrations at 24 (both of them P < 0.001) and 48 hours (both of them P < 0.001).
Additionally, previous studies reported the same findings regarding the correlation between Cr clearance and MTX concentration at the same time (7, 23, 24) . On the contrary, other studies such as Joannon et al (25) , Evans et al (26) and Relling et al (27) found that plasma MTX concentration was not correlated with Cr clearance. Likewise, Kerr et al (28) showed no correlation between MTX clearance and Cr clearance in 18 patients. The lack of agreement with our finding could be clarified by the truth that MTX regimens with lower doses, 1 g, 0.9-3.7 g, and 1-2 g/m 2 were administered in these studies respectively which were lower than the dosage in our study. The MTX concentrations in 24 and 48 hours were much lower as well, which means that patients in these studies might undergo a lesser degree of renal function impairment. Also, the kidney has a potent compensatory capacity (29) , thus minor injury has least effect on its clearance of MTX. Hence, the dose-responses effect of Cr clearance variation on MTX elimination may not be clear to a defined degree in these patients. Results revealed that usual evaluation of renal function could be appropriate for monitoring plasma MTX concentrations when using MTX in high doses over than 3 g/m 2 . Thus, straight monitoring of plasma MTX concentrations is not possible. Although main side effects of MTX such as mucositis, leucopenia and thrombocytopenia observed in patients in our study, we could not draw conclusions concerning association between serum MTX concentration and clinical outcome due to small sample size. Regression analysis by six variables and deleting low effective parameters was performed. We used backward model for doing the analysis. At first MTX concentration average was measured and then we defined it as a dependent variable. 
Conclusion
In summary this study demonstrated the relationship between renal function, Cr clearance and serum Cr and MTX concentration after HDMTX. According to the Cr change and Cr clearance level, physicians could monitor the MTX concentration and adjust alkalization and hydration as early as feasible. Hence, the toxicity of MTX could be reduced. In some institutions where MTX concentration detection cannot be performed, Cr and Cr clearance investigation can be a practical means to find out MTX concentration. For patients with high Cr level/ratio or low Cr clearance level, they are likely to undergo delayed MTX elimination. Thus, the modalities to improve renal function and increase MTX clearance should be applied accordingly. This study is just initial exploratory study and this model just has the goodness of fit in data. Therefore, validation studies for this model are recommended.
Limitation of the study
There are some limitations in our study that must be acknowledged. First, heterogeneity in the severity of disease might have influenced results like MTX infusion history before our study. Second, the short follow-up was not adequate to evaluate the extramedullary infiltration rate. Also 7-hydroxy MTX measurement in plasma and urine could help to define the pharmacokinetics of MTX as well as correlation with serum Cr. Direct measurement of glomerular filtration rate facilitates evaluating changes in renal functions more precisely. Also small sample size is another limitation.
